First-line use of Abilify more than doubles over past year for newly-diagnosed patients with bipolar disorder

19 November 2010

First-line use of Bristol Myers-Squibb(NYSE: BMY)/Otsuka's (TYO: 4523) Abilify (aripiprazole) has increased over the past year in newly-diagnosed patients from 4.1% patient share to 8.8%, according to Treatment Algorithms in Bipolar Disorder from advisory firm Decision Resources.

This says that uptake of Abilify in the first-line will continue among surveyed primary care physicians (PCPs): 26% of surveyed PCPs who prescribe Abilify indicate they expect to increase their first-line use of this agent over the next two years. Overall use of Abilify is expected to increase over the next two years as well: 25% and 50% of surveyed psychiatrists and PCPs, respectively, expect their overall use of Abilify to increase.

AstraZeneca’s Seroquel XR use also expected to rise

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK